Report from the 2nd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group
Language English Country England, Great Britain Media electronic
Document type Congress, Editorial
PubMed
28284218
PubMed Central
PMC5346258
DOI
10.1186/s12933-017-0508-8
PII: 10.1186/s12933-017-0508-8
Knihovny.cz E-resources
- MeSH
- Diabetes Mellitus, Type 2 complications drug therapy economics mortality MeSH
- Risk Assessment MeSH
- Hypoglycemic Agents adverse effects economics therapeutic use MeSH
- Cardiovascular Diseases economics etiology mortality prevention & control MeSH
- Clinical Trials as Topic MeSH
- Humans MeSH
- Evidence-Based Medicine MeSH
- Drug Costs MeSH
- Protective Factors MeSH
- Risk Factors MeSH
- Insurance, Health, Reimbursement MeSH
- Treatment Outcome MeSH
- Check Tag
- Humans MeSH
- Publication type
- Congress MeSH
- Editorial MeSH
- Names of Substances
- Hypoglycemic Agents MeSH
The 2nd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group was held on the 20th-21st October 2016 in Munich. This second Summit was organized in light of recently published CVOTs on diabetes, with the aim of serving as a reference meeting for discussion on this topic. Along with presentations on the results of the most recently published CVOTs, panel discussions on trial implications for reimbursement and the perspective of cardiologists and/or nephrologists, as well as on CVOTs weaknesses and potentials constituted the heart of the program. Future activities of the D&CVD EASD Study Group in 2017 include an annual meeting in Milano and the 3rd CVOT Summit on Diabetes of the D&CVD EASD Study Group, in Munich ( http://www.dcvd.org ).
Department of Cardiovascular and Metabolic Diseases IRCCS Multimedica Sesto San Giovanni Milan Italy
Forschergruppe Diabetes e 5 Munich Ingolstaedter Landstrasse 1 85764 Neuherberg Germany
Institut d’Investigacions Biomèdiques August Pi i Sunyer Barcelona Spain
See more in PubMed
Federal Drug Administration (FDA). Guidance for industry diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. 2008. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf. Accessed 20 Dec 2016.
European Medicines Agency (EMA). Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. Verfügbar unter. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129256.pdf (2012). Accessed 10 Jan 2016.
Standl E, Schnell O, McGuire DK. Heart failure considerations of antihyperglycemic medications for type 2 diabetes. Circ Res. 2016;118(11):1830–1843. doi: 10.1161/CIRCRESAHA.116.306924. PubMed DOI
Zannad F, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385(9982):2067–2076. doi: 10.1016/S0140-6736(14)62225-X. PubMed DOI
Zinman B, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128. doi: 10.1056/NEJMoa1504720. PubMed DOI
Marso SP, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322. doi: 10.1056/NEJMoa1603827. PubMed DOI PMC
Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–1844. doi: 10.1056/NEJMoa1607141. PubMed DOI
CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes
CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes
